Data system for pharmaceutical industry

By integrating data collection, health assessment, market analysis and drug safety monitoring modules in the pharmaceutical industry data system, the problem that existing systems cannot personalize the recommendation of drugs is solved, and the intelligent recommendation and sales rate of drugs are achieved.

CN118967040AInactive Publication Date: 2024-11-15北京健易保科技有限公司

Patent Information

Application Number
CN202411055265.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing pharmaceutical industry data system cannot personalize drug recommendations based on personal medical data background, resulting in low drug sales rates and inability to achieve intelligent drug recommendations.

Method used

A data system consisting of data collection module, health assessment module, pharmaceutical market analysis module, drug safety monitoring module and personalized medical promotion module was designed to comprehensively evaluate and analyze the clinical data and market data of patients to realize the intelligence of drugs. recommend. Specifically, it includes functions such as demand assessment, drug interaction inspection, drug safety monitoring and market analysis.

Benefits of technology

It has increased the sales rate of drugs, realized intelligent recommendation of drugs, made the drug production plan more clear, and could recommend drugs according to personalized needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118967040A_ABST
    Figure CN118967040A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicine data analysis, in particular to a data system for the medicine industry, and the data system comprises a data collection module which is used for collecting clinical data and market data in real time; the demand evaluation module is used for evaluating the state of the medicine required by the patient based on the clinical data of the patient; the medicine market analysis module is used for analyzing behaviors of the consumers based on the market data and formulating marketing and sales strategies; the medicine safety monitoring module is used for monitoring medicine safety; the personalized medical promotion module is used for integrating the drug state evaluation data and the drug market analysis data and carrying out intelligent production recommendation on the drugs; and the quality control module is used for managing and monitoring the quality of medical products and processes. According to the invention, personalized drug recommendation is carried out according to the personal medical data background, the sales rate of drugs is improved, intelligent drug recommendation can be realized, and thus the production plan of drugs is clearer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of medical data analysis, and specifically relates to a data system for the medical industry. Background Art

[0002] The pharmaceutical industry is an important part of my country's national economy. It is an industry that combines traditional and modern industries, and integrates the primary, secondary and tertiary industries. Its main categories include: chemical raw materials and preparations, Chinese medicinal materials, Chinese herbal medicines, Chinese patent medicines, antibiotics, biological products, biochemical drugs, radioactive drugs, medical devices, sanitary materials, pharmaceutical machinery, pharmaceutical packaging materials and pharmaceutical commerce. The pharmaceutical industry plays a very important role in protecting and promoting people's health and improving the quality of life. The data system in the pharmaceutical industry usually refers to the information technology system used to manage and process data related to drug production, circulation, sales, supervision, etc. These systems play a key role in the pharmaceutical industry and support the operation and decision-making of each link.

[0003] The existing data systems in the pharmaceutical industry cannot make personalized drug recommendations based on an individual’s medical data background, which reduces drug sales rates and fails to achieve intelligent drug recommendations. Summary of the invention

[0004] In view of the deficiencies of the prior art, the present invention provides a data system for the pharmaceutical industry to solve the above technical problems.

[0005] To achieve the above-mentioned object, the present invention provides the following technical solutions: a data system for the pharmaceutical industry, characterized by a data acquisition module, a health assessment module, a pharmaceutical market analysis module, a drug safety monitoring module, a personalized medical promotion module and a quality control module;

[0006] Data collection module: used to collect clinical data and market data in real time and store historical data;

[0007] Needs assessment module: used to assess the patient's required medication status based on the patient's clinical data;

[0008] Pharmaceutical market analysis module: used to analyze consumer behavior based on market data and formulate marketing and sales strategies;

[0009] Drug safety monitoring module: used to monitor drug safety and process abnormal information;

[0010] Personalized medical promotion module: used to integrate drug status assessment data and pharmaceutical market analysis data to make intelligent production recommendations for drugs.

[0011] Preferably, the needs assessment module includes:

[0012] Patient basic information and clinical data acquisition unit: obtain basic patient information, including name, age and gender, and clinical data, including diagnosis information, disease history, laboratory test results, pathology report and medication history;

[0013] Drug interaction examination unit: Based on the patient's basic information and clinical data, check the potential interactions between the drugs the patient is currently using and the drugs to be prescribed, including interactions between drugs and interactions between food and drugs;

[0014] Specific Drug Safety Monitoring Unit: Evaluate the safety of specific drugs for patients based on basic patient information, clinical data, and drug interactions, including the patient's drug allergy history and drug dosage adjustment needs;

[0015] Drug demand calculation unit: Based on the patient's basic information and clinical data, drug interactions and specific drug safety, it evaluates the most suitable drug or treatment plan, evaluates the drug's computing power requirements through the drug demand formula, and recommends drugs based on the drug's computing power requirements;

[0016] Efficacy prediction unit: Based on the patient's basic information and clinical data and historical data of similar patients, the efficacy prediction formula is used to predict and evaluate the efficacy of a specific treatment plan on the patient.

[0017] Preferably, the drug requirement formula is specifically:

[0018]

[0019] Among them, in the formula, F 总 is the total demand fraction of the drug, f 1 is the patient's basic drug demand score, f 2 is the drug interaction demand fraction, f 3 is the drug safety demand score, D is the safety score of the patient's basic drug demand, Q1 is the weight of the safety of the patient's basic drug demand, M is the safety score of drug interaction, Q2 is the weight of the safety of drug interaction, H is the safety score of a specific drug for the patient, and Q3 is the weight of the safety of a specific drug for the patient.

[0020] Preferably, the efficacy prediction formula is:

[0021] [PE=α0+α1x1+α2x2+α i x i …+α n x n ]

[0022] Among them, PE represents the expected efficacy of the treatment plan, (α0, α1, α2, …, α n) are the coefficients of the model, (x1, x2, …, x n ) is the feature input to the model, α i is the i-th model coefficient, x i is the i-th model feature.

[0023] Preferably, the pharmaceutical market analysis module specifically includes:

[0024] Market segmentation and positioning unit: divide the entire market into different market segments based on the characteristics of the patient group, disease type and treatment needs, and obtain the positioning of the company and products in each market segment;

[0025] Competitor Analysis Unit: Analyze competitors’ product features, pricing strategies, market share and market performance;

[0026] Competitive Advantage Analysis Unit: Evaluate your competitive advantages in the market and how to use these advantages to increase market share;

[0027] Consumer Behavior Analysis Unit: Obtain consumers’ purchase decision-making process, preferences, behavior patterns and consumption habits through market research and data analysis;

[0028] Demand Forecasting Unit: Based on historical data and market trends, it uses time series forecasting method formulas to predict the demand for specific products or treatment plans to help adjust supply chain and inventory management;

[0029] Marketing Strategy Unit: Develop pricing strategies, design promotional activities and sales promotion strategies based on forecast data to attract consumers and increase sales;

[0030] Market feedback and effect evaluation: Continuously monitor market conditions and product performance through market data and consumer feedback.

[0031] Preferably, the time series prediction method formula is specifically:

[0032]

[0033] in, is the predicted value of drug demand at time (t+1), yt-1 is the actual observed value of drug demand at the past (n) moments, and (n) is the time window size of the moving average.

[0034] Preferably, the drug safety monitoring module includes:

[0035] Drug abnormal event monitoring model establishment unit:

[0036] Screen out abnormal events based on real-time drug usage data; the abnormal events include but are not limited to: side effects, adverse reactions, and abnormal use;

[0037] Based on logistic regression, a risk probability prediction model for abnormal drug events was established;

[0038] Based on the drug abnormal event risk probability prediction model, each abnormal event in the historical drug use data is used as input, and the abnormal risk probability under the influence of each abnormal event is used as output;

[0039] Among them, the risk probability prediction model expression of drug abnormal events is:

[0040]

[0041] Where p(Y=1|X) is the abnormal risk probability of Y occurring under historical conditions X, and X i is the ith abnormal event in the historical maintenance log, e is an exponential function, V represents the total number of abnormal events, α0, α1, αi, and αv are all coefficients of the model;

[0042] Information management and recording unit: records drug batches, production information, regulatory approvals, and details of abnormal events;

[0043] Warning unit: Set up a drug safety warning system. When the abnormal risk probability exceeds 50%, issue drug safety warning information and related announcements to notify medical institutions, drug distributors and the public.

[0044] Emergency Response and Handling Unit: Develop emergency response plans for drug safety incidents, track and record the implementation of emergency response measures, and make improvement recommendations to optimize drug safety monitoring and management measures.

[0045] Preferably, the personalized medical promotion module includes:

[0046] Data fusion unit: data fusion based on drug demand data, efficacy prediction data and market demand data;

[0047] Personalized drug promotion unit: Based on the integrated data, establish a drug promotion model and carry out drug promotion.

[0048] Preferably, the drug promotion model formula is:

[0049] Y=β0+β1X1+β2X2+…+β n X n +∈

[0050] Where (Y) is the predictor variable, (X1, X2, …, X n ) is the predictor, β0 is the intercept, (β1, β2, …, β n ) is the regression coefficient, which indicates the influence of each independent variable on the dependent variable (Y), and ∈ is the error term.

[0051] Preferably, the base drug promotion model substitutes several allocation schemes into the model to obtain the prediction variables of several schemes;

[0052] Based on several allocated predictive variables, the drug that best fits the predictive variables is selected as the final allocation plan.

[0053] Compared with the prior art, the present invention has the following beneficial effects:

[0054] This application improves the sales rate of drugs by making personalized drug recommendations based on an individual's medical data background, and can realize intelligent drug recommendations, thereby making drug production plans clearer. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 It is a system framework diagram of the present invention. DETAILED DESCRIPTION

[0056] In order to better understand the present application, a more detailed description will be made of various aspects of the present application with reference to the accompanying drawings. It should be understood that these detailed descriptions are only descriptions of exemplary embodiments of the present application, and are not intended to limit the scope of the present application in any way. Throughout the specification, the same reference numerals refer to the same elements. The expression "and / or" includes any and all combinations of one or more of the associated listed items.

[0057] In the accompanying drawings, the size, dimensions and shapes of the elements have been slightly adjusted for ease of illustration. The drawings are for illustration only and are not strictly drawn to scale. As used herein, the terms "substantially", "approximately" and similar terms are used as terms of approximation, not as terms of degree, and are intended to illustrate the inherent deviations in measurements or calculations that would be recognized by a person of ordinary skill in the art. In addition, in this application, the order in which the processing of each step is described does not necessarily represent the order in which these processes occur in actual operation, unless otherwise specified or can be derived from the context.

[0058] It should also be understood that expressions such as "include", "including", "have", "contain" and / or "comprising" are open rather than closed expressions in this specification, which indicate the presence of the stated features, elements and / or components, but do not exclude the presence of one or more other features, elements, components and / or combinations thereof. In addition, when expressions such as "at least one of..." appear after a list of listed features, they modify the entire list of features rather than just the individual elements in the list. In addition, when describing embodiments of the present application, "may" is used to mean "one or more embodiments of the present application". And, the term "exemplary" is intended to refer to an example or illustration.

[0059] Unless otherwise defined, all words (including engineering terms and scientific and technological terms) used in this article have the same meaning as commonly understood by ordinary technical citizens in the field to which this application belongs. It should also be understood that, unless explicitly stated in this application, words defined in commonly used dictionaries should be interpreted as having the same meaning as their meaning in the context of the relevant technology, and should not be interpreted in an idealized or overly formal sense.

[0060] It should be noted that, in the absence of conflict, the embodiments and features of the embodiments in the present application can be combined with each other. The present application will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.

[0061] The present invention provides a technical solution: a data system for the pharmaceutical industry, the data system comprising: a data acquisition module, a health assessment module, a pharmaceutical market analysis module, a drug safety monitoring module, a personalized medical promotion module and a quality control module;

[0062] Data collection module: used to collect clinical data and market data in real time and store historical data;

[0063] Needs assessment module: used to assess the patient's required medication status based on the patient's clinical data;

[0064] Pharmaceutical market analysis module: used to analyze consumer behavior based on market data and formulate marketing and sales strategies;

[0065] Drug safety monitoring module: used to monitor drug safety and process abnormal information;

[0066] Personalized medical promotion module: used to integrate drug status assessment data and pharmaceutical market analysis data to make intelligent production recommendations for drugs.

[0067] Furthermore, the needs assessment module includes:

[0068] Patient basic information and clinical data acquisition unit: obtain basic patient information, including name, age and gender, and clinical data, including diagnosis information, disease history, laboratory test results, pathology report and medication history;

[0069] Drug interaction examination unit: Based on the patient's basic information and clinical data, check the potential interactions between the drugs the patient is currently using and the drugs to be prescribed, including interactions between drugs and interactions between food and drugs;

[0070] Specific Drug Safety Monitoring Unit: Evaluate the safety of specific drugs for patients based on basic patient information, clinical data, and drug interactions, including the patient's drug allergy history and drug dosage adjustment needs;

[0071] Drug demand calculation unit: Based on the patient's basic information and clinical data, drug interactions and specific drug safety, it evaluates the most suitable drug or treatment plan, evaluates the drug's computing power requirements through the drug demand formula, and recommends drugs based on the drug's computing power requirements;

[0072] Efficacy prediction unit: Based on the patient's basic information and clinical data and historical data of similar patients, the efficacy prediction formula is used to predict and evaluate the efficacy of a specific treatment plan on the patient.

[0073] Furthermore, the drug demand formula is as follows:

[0074]

[0075] Among them, in the formula, F 总 is the total demand fraction of the drug, f 1 is the patient's basic drug demand score, f 2 is the drug interaction demand fraction, f 3 is the drug safety demand score, D is the safety score of the patient's basic drug demand, Q1 is the weight of the safety of the patient's basic drug demand, M is the safety score of drug interaction, Q2 is the weight of the safety of drug interaction, H is the safety score of a specific drug for the patient, and Q3 is the weight of the safety of a specific drug for the patient.

[0076] Furthermore, the efficacy prediction formula is:

[0077] [PE=α0+α1x1+α2x2+α i x i …+α n x n ]

[0078] Among them, PE represents the expected efficacy of the treatment plan, (α0, α1, α2, …, α n ) are the coefficients of the model, (x1, x2, …, x n ) is the feature input to the model, α i is the i-th model coefficient, x i is the i-th model feature.

[0079] Furthermore, the pharmaceutical market analysis module specifically includes:

[0080] Market segmentation and positioning unit: divide the entire market into different market segments based on the characteristics of the patient group, disease type and treatment needs, and obtain the positioning of the company and products in each market segment;

[0081] Competitor Analysis Unit: Analyze competitors’ product features, pricing strategies, market share and market performance;

[0082] Competitive Advantage Analysis Unit: Evaluate your competitive advantages in the market and how to use these advantages to increase market share;

[0083] Consumer Behavior Analysis Unit: Obtain consumers’ purchase decision-making process, preferences, behavior patterns and consumption habits through market research and data analysis;

[0084] Demand Forecasting Unit: Based on historical data and market trends, it uses time series forecasting method formulas to predict the demand for specific products or treatment plans to help adjust supply chain and inventory management;

[0085] Marketing Strategy Unit: Develop pricing strategies, design promotional activities and sales promotion strategies based on forecast data to attract consumers and increase sales;

[0086] Market feedback and effect evaluation: Continuously monitor market conditions and product performance through market data and consumer feedback.

[0087] Furthermore, the time series prediction method formula is as follows:

[0088]

[0089] in, is the predicted value of drug demand at time (t+1), yt-1 is the actual observed value of drug demand at the past (n) moments, and (n) is the time window size of the moving average.

[0090] Furthermore, the drug safety monitoring module includes:

[0091] Drug abnormal event monitoring model establishment unit:

[0092] Screen out abnormal events based on real-time drug usage data; the abnormal events include but are not limited to: side effects, adverse reactions, and abnormal use;

[0093] Based on logistic regression, a risk probability prediction model for abnormal drug events was established;

[0094] Based on the drug abnormal event risk probability prediction model, each abnormal event in the historical drug use data is used as input, and the abnormal risk probability under the influence of each abnormal event is used as output;

[0095] Among them, the risk probability prediction model expression of drug abnormal events is:

[0096]

[0097] Where p(Y=1|X) is the abnormal risk probability of Y occurring under historical conditions X, and X i is the ith abnormal event in the historical maintenance log, e is an exponential function, V represents the total number of abnormal events, α0, α1, αi, and αv are all coefficients of the model;

[0098] Information management and recording unit: records drug batches, production information, regulatory approvals, and details of abnormal events;

[0099] Warning unit: Set up a drug safety warning system. When the abnormal risk probability exceeds 50%, issue drug safety warning information and related announcements to notify medical institutions, drug distributors and the public.

[0100] Emergency Response and Handling Unit: Develop emergency response plans for drug safety incidents, track and record the implementation of emergency response measures, and make improvement recommendations to optimize drug safety monitoring and management measures.

[0101] Furthermore, the personalized medical promotion module includes:

[0102] Data fusion unit: data fusion based on drug demand data, efficacy prediction data and market demand data;

[0103] Personalized drug promotion unit: Based on the integrated data, establish a drug promotion model and carry out drug promotion.

[0104] Furthermore, the drug promotion model formula is:

[0105] Y=β0+β1X1+β2X2+…+β n X n +∈

[0106] Where (Y) is the predictor variable, (X1, X2, …, X n ) is the predictor, β0 is the intercept, (β1, β2, …, β n ) is the regression coefficient, which indicates the influence of each independent variable on the dependent variable (Y), and ∈ is the error term.

[0107] Furthermore, in the base-point drug promotion model, several allocation schemes are substituted into the model to obtain the predictive variables of several schemes;

[0108] Based on several allocated predictive variables, the drug that best fits the predictive variables is selected as the final allocation plan.

[0109] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A data system for the pharmaceutical industry, characterized in that: The data system includes: data collection module, health assessment module, pharmaceutical market analysis module, drug safety monitoring module, personalized medical promotion module and quality control module; Data collection module: used to collect clinical data and market data in real time and store historical data; Needs assessment module: used to assess the patient's required medication status based on the patient's clinical data; Pharmaceutical market analysis module: used to analyze consumer behavior based on market data and formulate marketing and sales strategies; Drug safety monitoring module: used to monitor drug safety and process abnormal information; Personalized medical promotion module: used to integrate drug status assessment data and pharmaceutical market analysis data to make intelligent production recommendations for drugs; Quality Control Module: Used to manage and monitor the quality of pharmaceutical products and processes.

2. The data system for the pharmaceutical industry according to claim 1, characterized in that: The needs assessment module includes: Patient basic information and clinical data acquisition unit: obtain basic patient information, including name, age and gender, and clinical data, including diagnosis information, disease history, laboratory test results, pathology report and medication history; Drug interaction checking unit: based on the patient's basic information and clinical data, checking the potential interactions between the drugs currently being used by the patient and the drugs to be prescribed; the potential interactions include: interactions between drugs and interactions between food and drugs; Specific drug safety monitoring unit: Based on basic patient information, clinical data and drug interactions, the unit evaluates the safety of specific drugs for patients; the safety of specific drugs for patients includes: the patient's drug allergy history and the need for drug dosage adjustment; Drug demand calculation unit: Based on the patient's basic information and clinical data, drug interactions and specific drug safety, it evaluates the most suitable drug or treatment plan, evaluates the drug's computing power requirements through the drug demand formula, and recommends drugs based on the drug's computing power requirements; Efficacy prediction unit: Based on the patient's basic information and clinical data and historical data of similar patients, the efficacy prediction formula is used to predict and evaluate the efficacy of a specific treatment plan on the patient.

3. The data system for the pharmaceutical industry according to claim 2, characterized in that: The formula for drug demand is as follows: Among them, in the formula, F 总 is the total demand fraction of the drug, f 1 is the patient's basic drug demand score, f 2 is the drug interaction demand fraction, f 3 is the drug safety demand score, D is the safety score of the patient's basic drug demand, Q1 is the weight of the safety of the patient's basic drug demand, M is the safety score of drug interaction, Q2 is the weight of the safety of drug interaction, H is the safety score of a specific drug for the patient, and Q3 is the weight of the safety of a specific drug for the patient.

4. The data system for the pharmaceutical industry according to claim 2, characterized in that: The efficacy prediction formula is: [PE=α0+α1x1+α2x2+α i x i …+a n x n ] Among them, PE represents the expected efficacy of the treatment plan, (α0, α1, α2, …, α n ) are the coefficients of the model, (x1,x2,…,x n ) is the feature input to the model, α i is the i-th model coefficient, x i is the i-th model feature.

5. The data system for the pharmaceutical industry according to claim 1, characterized in that: The pharmaceutical market analysis module specifically includes: Market segmentation and positioning unit: divide the entire market into different market segments based on the characteristics of the patient group, disease type and treatment needs, and obtain the positioning of the company and products in each market segment; Competitor Analysis Unit: Analyze competitors’ product features, pricing strategies, market share and market performance; Competitive Advantage Analysis Unit: Evaluate your competitive advantages in the market and how to use these advantages to increase market share; Consumer Behavior Analysis Unit: Obtain consumers’ purchase decision-making process, preferences, behavior patterns and consumption habits through market research and data analysis; Demand Forecasting Unit: Based on historical data and market trends, it uses time series forecasting method formulas to predict the demand for specific products or treatment plans to help adjust supply chain and inventory management; Marketing Strategy Unit: Develop pricing strategies, design promotional activities and sales promotion strategies based on forecast data to attract consumers and increase sales; Market feedback and effect evaluation: Continuously monitor market conditions and product performance through market data and consumer feedback.

6. The data system for the pharmaceutical industry according to claim 5, characterized in that: The specific formula of the time series prediction method is: in, is the predicted value of drug demand at time (t+1), y t-1 is the actual drug demand observation value in the past (n) moments, and (n) is the time window size of the moving average.

7. The data system for the pharmaceutical industry according to claim 1, characterized in that: The drug safety monitoring module includes: Drug abnormal event monitoring model establishment unit: Screen out abnormal events based on real-time drug usage data; the abnormal events include but are not limited to: side effects, adverse reactions, and abnormal use; Based on logistic regression, a risk probability prediction model for abnormal drug events was established; Based on the drug abnormal event risk probability prediction model, each abnormal event in the historical drug use data is used as input, and the abnormal risk probability under the influence of each abnormal event is used as output; Among them, the risk probability prediction model expression of drug abnormal events is: Where p(Y=1|X) is the abnormal risk probability of Y occurring under historical conditions X, and X i is the ith abnormal event in the historical maintenance log, e is an exponential function, V represents the total number of abnormal events, α0, α1, α i , α v are the coefficients of the model; Information management and recording unit: records drug batches, production information, regulatory approvals, and details of abnormal events; Warning unit: Set up a drug safety warning system. When the abnormal risk probability exceeds 50%, issue drug safety warning information and related announcements to notify medical institutions, drug distributors and the public; Emergency Response and Handling Unit: Develop emergency response plans for drug safety incidents, track and record the implementation of emergency response measures, and make improvement recommendations to optimize drug safety monitoring and management measures.

8. The data system for the pharmaceutical industry according to claim 1, characterized in that: The personalized medical promotion module includes: Data fusion unit: data fusion based on drug demand data, efficacy prediction data and market demand data; Personalized drug promotion unit: Based on the integrated data, establish a drug promotion model and carry out drug promotion.

9. The data system for the pharmaceutical industry according to claim 1, characterized in that: The drug promotion model formula is: Y=β0+β1X1+β2X2+…+β n X n +∈ Among them, (Y) is the predictor variable, (X1,X2,…,X n ) is the predictor, β0 is the intercept, (β1,β2,…,β n ) is the regression coefficient, which indicates the influence of each independent variable on the dependent variable (Y), and ∈ is the error term.

10. The data system for the pharmaceutical industry according to claim 9, characterized in that: The basic drug promotion model, several allocation schemes are substituted into the model to obtain the predictive variables of several schemes; Based on several allocated predictive variables, the drug that best fits the predictive variables is selected as the final allocation plan.

Citation Information

Patent Citations

  • Medical sales prediction system and method based on IPSO-LSTM model

    CN115760210A

  • Drug market data analysis method and system based on big data

    CN117196694A

  • Pediatric drug complication monitoring system

    CN117457215A

  • Intelligent identification and prevention system for adverse drug reaction

    CN118053541A

Cited By

  • Intelligent promotion comprehensive processing system based on e-commerce information

    CN119884491A

  • Marketing activity generation method and device based on sales data analysis

    CN119963234A